Plain-English translation of NCT05332002 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing sFOLFOXIRI, a chemotherapy treatment that alternates between two different drug combinations given every two weeks. The study also offers an optional immunotherapy medication called nivolumab. Researchers want to see if this rotating approach works better than standard chemotherapy for advanced stomach and esophageal cancers.
Current treatments for advanced stomach and esophageal cancer do not work well enough for many patients. This trial is testing whether alternating between two chemotherapy combinations can help more patients respond to treatment while staying as safe as possible.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy every two weeks in an alternating pattern: one infusion combination, then two weeks later a different combination, continuing this cycle throughout the study. Some participants may also receive an optional immunotherapy infusion every two weeks. You would have regular blood tests and imaging scans to check how you are responding to treatment. The study involves scheduled clinic visits and lasts until your cancer progresses or side effects become unmanageable.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States